{"Title": "Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide", "Year": 2016, "Source": "Nat. Rev. Urol.", "Volume": "13", "Issue": 12, "Art.No": null, "PageStart": 697, "PageEnd": 698, "CitedBy": 19, "DOI": "10.1038/nrurol.2016.212", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84994129947&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Androstenes", "Antineoplastic Agents", "Drug Resistance, Neoplasm", "Humans", "Male", "Phenylthiohydantoin", "Prostatic Neoplasms", "Prostatic Neoplasms, Castration-Resistant", "Receptors, Androgen"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-84994129947", "SubjectAreas": [["Urology", "MEDI", "2748"]], "AuthorData": {"9740870900": {"Name": "Attard G.", "AuthorID": "9740870900", "AffiliationID": "60010337", "AffiliationName": "Gerhardt Attard Is at the Centre of Evolution and Cancer, The Institute of Cancer Research"}, "55881902100": {"Name": "Antonarakis E.S.", "AuthorID": "55881902100", "AffiliationID": "60017166", "AffiliationName": "The Royal Marsden NHS Foundation Trust"}}}